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A B S T R A C T
In this study, the CaP/pDNA nanoparticles were prepared using Triton X-100/Butanol/
Cyclohexane/Water reverse microemulsion system. Optimization of preparation conditions
was based on evaluation of particle size by Box–Behnken design method. The particle sizes
of the optimized CaP/pDNA nanoparticles were found to be 60.23 ± 4.72 nm, polydispersity
index was 0.252 and pDNA encapsulate efficiency was more than 90%. The optimized CaP/
pDNA nanoparticles have pH sensitivity and biocompatibility. Further, optimized CaP/
pDNA nanoparticles showed higher transfection efficiency.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This









Calcium phosphate (CaP) has been widely used as a gene carrier
to mediate pDNA into mammalian cells [1,2] because of its good
biocompatibility, biodegradability, as well as easy handling and
preparation [3]. However, there exist many factors that affect
the transfection of CaP, especially the size and size distribu-
tion of CaP play an important role in the transfection progress
[4]. According to previous reports, small particle size was ben-
eficial to cell transfection and expression; in addition, nano-
sized non-agglomerated precipitate is a key parameter for
effective calcium phosphate nanoparticle transfection [5] .
In order to get uniform nanoparticles, many size-controlled
methods have been reported, including precipitation method,
hydrothermal method, sol process, autocombustion method
and reverse microemulsion method [6,7]. The size and size dis-
tribution of CaP are difficult to control by means of the chemical
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precipitation and hydrothermal methods due to the fast nucle-
ation, aggregation and subsequent anisotropic growth of crystal
faces [7]. Rapid growth of the particles resulting in sharp in-
crease in diameter is thus a big hurdle which must be
eliminated for efficient gene delivery and expression into the
cells [8].
The reverse microemulsion method is an effective ap-
proach to regulate the size and size distribution of CaP crystals,
which can restrict strictly the nucleation and growth of CaP in
the uniform and narrow channels of the microreactors in the
microemulsion system [9]. Moreover, emulsion droplets can also
inhibit excess agglomeration of particles, since the surfactants
can be absorbed onto the surface of particles [10,11]. However,
properties of formulations are influenced by various factors, such
as the pH value of solution, ion concentration, stirring rate, re-
action time and reaction temperature [12,13]. Up to now, many
researchers focusing on the influence of a single factor on par-
ticle size have investigated the preparation conditions of CaP/
pDNA nanoparticles; nevertheless,statistical methods were rarely
employed to optimize preparation conditions.
In order to prepare nano-sized CaP/pDNA particles, the
current research adopted the reverse microemulsion to prepare
CaP/pDNA nanoparticles (Fig. 1). The formulations were opti-
mized using the three-factor three-level Box–Behnken design.
Furthermore, the characters of the optimized CaP/pDNA
nanoparticles, in vitro release, in vitro cell cytotoxic, and trans-
fection were further evaluated.
2. Materials and methods
2.1. Materials
Analytical-grade calcium chloride (99.99%) and sodium phos-
phate were purchased from Aldrich. n-Butyl alcohol,
cyclohexane and Triton X-100 were provided by Sinopharm
(Shanghai, China). Reporter plasmid pDsRed-M-N1 was a gift
from Tsinghua University. Endo-free Plasmid mini kits were pur-
chased from Omega Bio-Tek (USA). Dulbecco’s minimum
essential medium (DMEM) growth medium, fetal bovine serum
(FBS) and penicillin–streptomycin (P/S) were offered by Gibco
(USA). Hoechst 33258 was obtained from the Beyotime Insti-
tute of Biotechnology (Haimen, Jiangsu, China). Lipofectamine
2000 was purchased from Invitrogen Life Technologies (USA).
All other chemicals were commercially available reagents of
at least analytical grade.
2.2. Preparation of CaP/pDNA nanoparticles
According to previous reported literatures, Triton X-100 and
Butanol were used as mixed emulsifiers; hexane was used as
oil phase; 100 μl of calcium chloride solution (1.0M) and 500 ng
of pDNA were added to oil phase and stirred for 1 h to prepare
microemulsion A. In the same way, 100 μl of Na3PO4 (1.0 M) was
added to oil phase and agitated for 1 h to form microemulsion
B. The microemulsion B was added to the microemulsion A,
and the resulting solution was further stirred for another 12 h
at a certain speed. Then, the appropriate amount of absolute
ethyl alcohol was added to break the emulsion. After that, the
mixture was centrifuged for 10 min at 12,000 rpm at 4 °C. The
sediment was resuspended in redistilled water after being
washed with absolute ethyl alcohol for three times.
2.3. Optimization of CaP/pDNA nanoparticles using Box–
Behnken design
Based on single factor study, we choose three main techno-
logical factors, the concentration ratio of Ca2+ to PO43− (X1), the
pH (X2), and the stirring speed (X3), to evaluate the interac-
tion effects of those factors in the formulations. The particle
size (Y) was chosen as the response. Then, the Box–Behnken
design (3-factor, 3-level) was used to optimize the test and a
total of 17 experimental runs were generated by Design-
Expert software. All variables were investigated at three different
levels (Table 1).
Fig. 1 – Schematic diagram of nanoparticle preparation by microemulsion.
Table 1 – Central composite design factors and levels.
Factors Range and levels
−1 0 1
X1 100 200 300
X2 7 9 11
X3 400 600 800
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2.4. Characterization of nanoparticles
2.4.1. Particle size analysis
Particle sizes of CaP/pDNA nanoparticles were measured by
dynamic light scattering method (Malvern, Worcestershire, UK)
with a computerized inspection system at 25 ± 1 °C and at a
scattering angle of 90°. All sizes were taken in triplicate and
the mean diameter was expressed as intensity diameter.
2.4.2. Transmission electron microscopy
The morphology of CaP/pDNA nanoparticles was observed by
transmission electron microscopy (TEM,Tecnai G220, FEI, USA).
Freshly prepared calcium phosphate nanoparticles were diluted
with water and then dropped in the copper mesh wherein the
surface was covered by carbon membrane. Phosphotungstic acid
(2.0%) was used for negative dyeing, and the morphology and
size of calcium phosphate were observed under the transmis-
sion electron microscope.
2.4.3. Entrapment efficiency (E%)
The entrapment efficiency was determined via fluorescence
method. The CaP/pDNA nanoparticles in the microemulsion
were separated by ultracentrifugation (13,000 rpm for 1 h at 4 °C)
and dissolved in acidic buffer (pH 5.5) after washing. The
amount of pDNA released from the nanoparticles [DNA]r was
estimated using Hoechst 33258 fluorescence analytical methods.
The entrapment efficiency (E%) was calculated by the follow-
ing equation: E% = [DNA]r/[DNA]0 × 100%, and all experiments
were repeated in triplicate.
2.5. Release of pDNA in vitro
The release of pDNA from the nanoparticles is an important pa-
rameter for determining the efficacy of a gene delivery
system. Release of pDNA was investigated in this study. In brief,
the nanoparticles containing 500 ng of pDNA were suspended
in 1 mL release medium at pH 7.4 or 5.5 and incubated for dif-
ferent times at 37 °C on a horizontal shaker at 100 rpm. Samples
were taken at each time point, the nanoparticle suspensions were
centrifuged at 13,000 rpm, and the supernatant was com-
pletely withdrawn. The amount of the pDNA released in the
supernatant was determined by Hoechst 33258 staining assay.
2.6. Cell culture
HepG-2 cells were obtained from cell bank of the Chinese
Academy of Sciences (Shanghai, China) and maintained in
DMEM medium supplemented with 10% FBS and 1% antibi-
otics (penicillin/streptomycin) at 37 °C in a 5% CO2 atmosphere.
2.7. In vitro cytotoxicity assays
The cytotoxicity of blank CaP nanoparticles, pDNA and CaP/
pDNA against HepG-2 cells was investigated by the standard
MTT assay. HepG-2 cells (1 × 104 cells/well) were seeded in 96-
well plates and subsequently cultured overnight. Then, cells
were treated with CaP, pDNA and CaP/pDNA. After cells were
incubated for different times, 20 μl of MTT (5 mg/ml) was added
to each well. The cells were further incubated for 4 h and then
150 μl of DMSO was added to dissolve the formazan crystals
formed in the live cells. The absorbance of the samples was
measured at 490 nm. The results were expressed as percent-
age viability of control cells and were taken in triplicate.
2.8. In vitro transfection and red fluorescence protein
(RFP) quantification
The transfection efficiency of nanoparticles was assessed in
HpeG-2 cells. The cells were seeded at a density of 4 × 105 cells/
well into 6-well plates. When HpeG-2 cells grew to about 80%
confluence, the medium was removed and washed twice
with PBS. Then, the CaP/pDNA nanoparticles, free pDNA,
Lipofectamine in free FBS DMEM were added to the cells with
a final pDNA concentration of 500 ng/well. After a 4-h incu-
bation, the cell culture medium was replaced with fresh serum
medium and the cells were allowed to incubate for different
times. Then, cells were rinsed twice with PBS and treated with
Hoechst 33258 (10 mg/ml) at 37 °C for 30 min, followed by
washing with PBS (pH 7.4) and soaking in 4% paraformalde-
hyde for 30 min. The transfection and expression of red
fluorescence protein were determined using a laser scan con-
focal microscope (LSCM, Olympus, Japan) and quantified by flow
cytometry (BD Bioscience, Bedford, MA).
3. Results and discussion
3.1. Nanoparticle preparation and optimization
Based on our previous research, the optimized reverse
microemulsion method was used to prepare CaP/pDNA
nanoparticles. It was well known that the size of CaP/pDNA
was critically related to synthetic methods and synthetic pa-
rameters. Especially, parameters like initial concentration, Ca/P
molar ratio of the precursors [14], reaction temperature, initial
and final pH values, aging time and stirring speed in solution
played critical roles in modulating the size and size distribu-
tion of CaP/pDNA nanoparticles [15,16].
In order to balance the relationships between those factors
and prepare equally distributed nano-sized CaP/pDNA par-
ticles, three significant parameters were chosen (X1: the
concentration ratio of Ca2+ to PO43−, X2: the system pH, X3: the
stirring speed) to optimize the preparation conditions using the
Box–Behnken design methods [17,18]. This design was suitable
for exploring quadratic response surfaces and constructing second
order polynomial models. Each factor was assigned to three dif-
ferent levels as low, middle and high, respectively, which were
listed in Table 1.All possible combinations were shown in Table 2.
According to the Box–Behnken design,17 experimental runs were
carried out in random order. Analysis of variance for the re-
sponse surface and the quadratic model were shown in Table 3.
As shown in the results, the model F-value of 16.56 implied
that the model was significant. Values of “Prob > F” less than
0.050 indicated that model terms were significant. In this study
“Prob > F” was 0.0006, which suggested that there was only a
0.06% chance that a “model F-value” could occur due to noise.
The P-value for “Lack of Fit” test was 0.1476 which implied that
the Lack of Fit was not significantly relative to the pure error,
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indicating the quadratic model was adequate. As shown in
Table 3, X1, X2, X3, X12, X22, X32 were significant model terms. The
equation relating to responses of particle size by the design
was given below:
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This regression equation described quantitatively the effects
of three independent variables (X1, X2, X3) on index and their
correlations. It could be predicted to obtain response value of
a random formula within the range of designed factor and level
by regression equations. This model could be used to navi-
gate the design space.
In the experimental process, the three independent vari-
ables would interact with other levels. Fig. 2A–C shows that
the particle size was investigated when two variables were kept
in the experimental range and the other variable was fixed.
The three graphs had similar trends, particle size decreased
with the increase of each variable, then increased after a criti-
cal value. All of them had a lowest point in three-dimensional
graph, illustrating that the size of particles had a minimum
value in the experimental range. During the preparation of CaP/
pDNA nanoparticles, the three factors interacted with each
other. As reported, the ratio of Ca to P affected nucleation and
crystal growth, while the pH changed crystal nucleus forma-
tion conditions and different crystal nucleus morphology.
Moreover, the stirring speed could affect the movement rate
of ions and nucleation rate of crystals. In conclusion, all those
factors could result in the change of particle sizes by a differ-
ent mechanism. Finally, we intuitively and clearly found out
the point of minimum value of the three dimensional graphs.
Based on the studies above, the optimized experimental con-
ditions were shown as follows: the ratio between the calcium
to phosphorus (Ca:P) was 179.59, the pH was 8.48, and the stir-
ring speed was 710.75. Optimized nanoparticle formulation had
mean size of 60.23 nm, PDI was 0.252, almost the same as the
predicted value of 59.79. Therefore, the results of the experi-
ments were close to the predicted values obtained from
optimization analysis using desirability function, suggesting
that the results of optimization were reliable and reasonable.
3.2. Characterization of CaP/pDNA nanoparticles
CaP/pDNA nanoparticles were prepared using the optimal
method. Hoechst 33258 fluorescence analytically showed that
the encapsulation efficiency (EE %) was around 90%. The size
distribution and particle size of the CaP/pDNA nanoparticles
were measured with Mastersizer 2000. Fig. 3A shows that the
nanoparticles had small particle size and uniform distribu-
tion. The mean particle size was 60.23 ± 4.72 nm, and the
polydispersity index was 0.252. The size and morphology of
nanoparticles were further characterized by TEM. Fig. 3B shows
that nanoparticles had spherical-like morphology and uniform
particle size.
3.3. Release of pDNA in vitro
It was well known that the release of pDNA from nanoparticles
served as an important parameter for determining the effi-
cacy of a gene delivery system [19]. Therefore, the release of
pDNA from nanoparticles was investigated at different pH in
this study. Fig. 4 shows the results of pDNA release from
nanoparticles at different pH values. The pDNA release study
indicated that very few encapsulated pDNA (less than 10.27%)
released from the nanoparticles at pH 7.4. The pDNA release
rate increased remarkably when the pH decreased to 5.5. At
pH 5.5, more than 50% of the encapsulated pDNA released from
nanoparticles at the first 2 h, and more than 90% of the en-
capsulated pDNA released at 12 h. The pH-dependent manner
indicated that nanoparticles could prevent pDNA graduating
and increase the pDNA stability in physiological environ-
ment. Moreover, the result supported the supposition that










1 100 7.00 600.00 67.23
2 200 9.00 600.00 59.23
3 200 9.00 600.00 61.08
4 200 11.00 400.00 73.25
5 100 9.00 400.00 65.57
6 200 7.00 800.00 62.35
7 300 7.00 600.00 68.58
8 200 9.00 600.00 61.76
9 100 11.00 600.00 71.64
10 300 11.00 600.00 75.68
11 200 7.00 400.00 71.09
12 100 9.00 800.00 63.77
13 200 9.00 600.00 62.05
14 300 9.00 800.00 68.24
15 300 9.00 400.00 70.29
16 200 9.00 600.00 60.28
17 200 11.00 800.00 69.23
Note: X1: representative of the ratio of Ca2+ and PO43−; X2: the pH of
system; X3: the stirring speed.







Model 377.96 9 42.00 16.56 0.0006
X1 26.57 1 26.57 10.48 0.0143
X2 52.79 1 52.79 20.81 0.0026
X3 34.49 1 34.49 13.60 0.0078
X1X2 1.81 1 1.81 0.71 0.4263
X1X3 0.016 1 0.016 6.160E−003 0.9396
X2X3 5.57 1 5.57 2.20 0.1820
X12 65.53 1 65.53 25.83 0.0014
X22 149.44 1 149.44 58.91 0.0001
X32 19.33 1 19.33 7.62 0.0281
Residual 17.76 7 2.54
Lack of fit 12.49 3 4.16 3.16 0.1476
Pure error 5.27 4 1.32
Cor Total 395.72 16
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nanoparticles could dissociate in the weak acidic environ-
ment (pH 5.5).
3.4. Cytotoxicity of complexes
In this research, the toxic effects of CaP/pDNA nanoparticles
against HepG-2 cells were determined using MTT assay. Fig. 5
shows that the CaP nanoparticles, pDNA and CaP/pDNA
nanoparticles did not exhibit any significant cytotoxicity against
HepG-2 cells at 24 h (P > 0.05); the cell viability was greater than
97%. Although the viability of HepG-2 cells for 48 h and 72 h
was slightly lower than that for 24 h, they had no statistical
differences (P > 0.05) between each time points. Some research-
ers have reported that intracellular calcium concentration would
lead to cell death [20], but there were some other research that
reported that increased intracellular Ca2+ would pump out of
cells by Ca2+ pumps, this mechanism would overcome calcium
toxicity [21]. These findings further confirmed that CaP/
pDNA nanoparticles were safe and biocompatible in vitro.
3.5. In vitro transfection and expression studies
It was well understood that transfection and expression
efficiency of exogenous gene depended on various factors
such as complex size and morphology, stability in solutions,
ability to bind and release pDNA, cytotoxicity and biocompat-
ibility [22]. In this investigation, in vitro transfection
and expression of RFP were determined in HepG-2 cells by
LSCM and flow cytometry. Fig. 6A shows the expression of
RFP after being treated with CaP/pDNA nanoparticles at
different times. The results showed that the transfection
efficiency of packaged pDNA was time dependent. When
cells were treated with nanoparticles for 1 h, there was no
RFP produced, the fluorescence intensity was invisible and
therefore negligible, but the fluorescence intensity increased
after 2 h. Fig. 6B shows that there was a difference in
fluorescence intensity among these three groups. No fluores-
cence was found in free pDNA; in contrast, the fluorescence
of optimized CaP/pDNA nanoparticles was stronger than
pDNA. But the fluorescence intensity is slightly weaker than
Lipofectamine. The pDNA expression was also quantified by
flow cytometry. Fig. 6C shows that the results are in accord
with the experimental results of LSCM. Therefore, this study
identified that optimized CaP/pDNA nanoparticles have the
same expression ability with Lipofectamine 2000 because
optimized CaP carriers could protect pDNA from being de-
graded after being entrapped in endosomes by its pH-
sensitivity [23].
Fig. 2 – 3-D surface response diagrams. (A) Response surface plot for the effect of the ratio of the Ca2+ to the PO43− and the pH
on the particle size. (B) Response surface plot for the effect of the pH and the stirring speed on the particle size. (C)
Response surface plot for the effect of the ratio of the Ca2+ to the PO43− and the stirring speed on the particle size.
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Fig. 3 – Characterization of nanoparticles. (A) The particle size measured by DLS (n = 3). (B) Transmission electron
micrographs of nanoparticles.
Fig. 4 – The pH-sensitive release of pDNA from
nanoparticles at different time points in pH 7.4 and pH 5.5
environment (n = 3).
Fig. 5 – In vitro cytotoxicity studies of pDNA, CaP and CaP/
pDNA nanoparticles (pDNA at 500 ng/well) with different
times (n = 3).
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4. Conclusion
In the present study, the CaP/pDNA nanoparticles were pre-
pared using reverse microemulsion method and optimized with
employing Box–Behnken design.The nanoparticle size was close
to the predicted one generated by Design. The optimized
nanoparticles had smaller particle size, uniform distribution
and higher encapsulation efficiency. The MTT results showed
that the optimized CaP/pDNA nanoparticles had better bio-
compatibility in vitro. In vitro transfection study indicated that
optimized formulations showed good transfection efficiency.
We could draw a conclusion that Box–Behnken design method
could be used in the optimization of nano-sized CaP/pDNA
particles.
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